Asunercept

Active substance Asunercept
Domain Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Brain cancer
Extended indication Treatment of recurrent glioblastoma

Product

Manufacturer Apogenix
Mechanism of action Immunostimulation
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional comments Asunercept works by attaching to a protein known as the CD95 ligand, which triggers a natural process that leads to cell death (apoptosis).

Registration

Registration route Centralised (EMA)
Type of trajectory Accelerated assessment
Particularity New medicine with Priority Medicines (PRIME)
Orphan drug Yes
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found
Additional comments IV 800 mg weekelijks

Expected patient volume per year

Patient volume

< 500

Market share is generally not included unless otherwise stated.

References NKR; expertopinie
Additional comments In Nederland zijn er jaarlijks ongeveer 1.100 patiënten met de diagnose glioma waarbij er ongeveer 800 de diagnose glioblastoma krijgen. Hiervan worden er tussen de 60-70% primair behandeld met chemoradiatie. Meer dan 90% van de glioblastoma's zijn recurrent. Er zullen dus maximaal 500 patiënten mogelijk in aanmerking komen voor deze behandeling.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No

Other information

There is currently no futher information available.